GlaxoSmithKline Pharmaceuticals (GSK India) on Wednesday reported 13% year-on-year (YoY) jump of net profit to Rs 131 crore for the quarter ended June 2023 led by robust volumes, price hikes and recovery of its vaccine business. The said it maintained its gross margins despite the National List of Essential Medicines (NLEM) impact, while EBITDA margins declined 1% to 19.1% on account of new product launch investments led by Shingrix.
